Nashville Biosciences

Executive Summary

Nashville Biosciences (NashBio) is an early-stage biotechnology company that provides advanced data solutions for biopharmaceutical, diagnostics, and AI research. Founded in 2019 and headquartered in Nashville, Tennessee, the company leverages a vast, de-identified repository of real-world clinical, genomic, and medical imaging data sourced from Vanderbilt University Medical Center (VUMC). This unique data asset enables precision medicine and novel discovery through curated, multimodal datasets tailored to specific client use cases. Currently in Phase 1, NashBio is positioned to capitalize on the growing demand for high-quality real-world evidence in drug development and clinical AI. The company's key differentiator is its access to deeply phenotyped longitudinal data from a major academic medical center, which can accelerate research timelines and reduce costs for partners. However, as a private company with limited public financial information, its near-term trajectory depends on securing additional funding, forming strategic partnerships, and demonstrating the value of its data solutions through client wins.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership announcement40% success
• Q4 2026Series A funding round50% success
• Q2 2026Expansion of imaging data capabilities or new dataset release60% success